Genetic Technologies Ltd (NASDAQ:GENE) — Market Cap & Net Worth
Market Cap & Net Worth: Genetic Technologies Ltd (GENE)
Genetic Technologies Ltd (NASDAQ:GENE) has a market capitalization of $3.71 Million ($3.71 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29226 globally and #5969 in its home market, demonstrating a -2.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genetic Technologies Ltd's stock price $1965.70 by its total outstanding shares 4847240 (4.85 Million). Also see Genetic Technologies Ltd asset portfolio for a full breakdown of the balance sheet.
Genetic Technologies Ltd Market Cap History: 2015 to 2026
Genetic Technologies Ltd's market capitalization history from 2015 to 2026. Data shows growth from $259.81 Million to $9.53 Billion (42.83% CAGR). Also see Genetic Technologies Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Genetic Technologies Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genetic Technologies Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Genetic Technologies Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.49x
Genetic Technologies Ltd's market cap is 0.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $259.81 Million | $2.01 Million | -$8.81 Million | 129.14x | N/A |
| 2016 | $104.70 Million | $824.59K | -$8.46 Million | 126.97x | N/A |
| 2017 | $112.46 Million | $518.51K | -$8.40 Million | 216.88x | N/A |
| 2018 | $53.32 Million | $189.25K | -$5.46 Million | 281.74x | N/A |
| 2019 | $48.23 Million | $25.44K | -$6.83 Million | 1895.54x | N/A |
| 2020 | $87.25 Million | $9.86K | -$6.30 Million | 8845.33x | N/A |
| 2021 | $45.56 Million | $120.55K | -$7.21 Million | 377.96x | N/A |
| 2022 | $22.54 Million | $6.79 Million | -$7.13 Million | 3.32x | N/A |
| 2023 | $11.63 Million | $10.35 Million | -$11.75 Million | 1.12x | N/A |
| 2024 | $3.73 Million | $7.66 Million | -$12.02 Million | 0.49x | N/A |
Competitor Companies of GENE by Market Capitalization
Companies near Genetic Technologies Ltd in the global market cap rankings as of September 18, 2026. Review Genetic Technologies Ltd (GENE) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Genetic Technologies Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #163 globally with a market cap of $147.17 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #472 globally with a market cap of $57.08 Billion USD ( CN¥390.06 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #577 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $648.43 |
| #163 | Danaher Corporation | NYSE:DHR | $147.17 Billion | $208.36 |
| #472 | WuXi AppTec Co Ltd | SHG:603259 | $57.08 Billion | CN¥157.71 |
| #577 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $345.34 |
Genetic Technologies Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Genetic Technologies Ltd's market cap moved from $259.81 Million to $ 9.53 Billion, with a yearly change of 42.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.53 Billion | +255185.71% |
| 2024 | $3.73 Million | -67.92% |
| 2023 | $11.63 Million | -48.39% |
| 2022 | $22.54 Million | -50.53% |
| 2021 | $45.56 Million | -47.78% |
| 2020 | $87.25 Million | +80.90% |
| 2019 | $48.23 Million | -9.55% |
| 2018 | $53.32 Million | -52.59% |
| 2017 | $112.46 Million | +7.41% |
| 2016 | $104.70 Million | -59.70% |
| 2015 | $259.81 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Genetic Technologies Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.71 Million USD |
| MoneyControl | $3.71 Million USD |
| MarketWatch | $3.71 Million USD |
| marketcap.company | $3.71 Million USD |
| Reuters | $3.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more